Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive summary

Canadian Journal of Cardiology

Volumn 25, Issue 4, 2009, Pages 197-205

  Haddad, Haissan ^a   Isaac, D ^b   Legare, J F ^c   Pflugfelder, P ^d   Hendry, P ^e   Chan, M ^e   Cantin, B ^f   Giannetti, N ^g   Zieroth, S ^h   White, M ⁱ   Warnica, W ^b   Doucette, K ^e   Rao, V ^j   Dipchand, A ^j   Cantarovich, M ^g   Kostuk, W ^d   Cecere, R ^g   Charbonneau, Eric ^f   Ross, H ^j   Poirier, N ⁱ  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIMETABOLITE; ARGIPRESSIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; ILOPROST; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISOPRENALINE; LIOTHYRONINE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OKT 3; PROSTAGLANDIN E1; SILDENAFIL; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; CARDIAC GRAFT REJECTION; CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE SEVERITY; DONOR; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; EXTRACORPOREAL CIRCULATION; FUNCTIONAL STATUS; GAS ANALYSIS; GRAFT FAILURE; GRAFT RECIPIENT; HEALTH STATUS; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEPHROTOXICITY; PLASMAPHERESIS; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REOPERATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; CLASSIFICATION; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HEART RIGHT VENTRICLE FUNCTION; IMMUNOLOGY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; POSTOPERATIVE COMPLICATION;

EVIDENCE-BASED MEDICINE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUROMONAB-CD3; OXYGEN CONSUMPTION; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; REOPERATION; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 65349172946     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70061-3     Document Type: Conference Paper

References (96)

1. 2001 Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. Can J Cardiol 2003; 19:620-54.
2. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006;25:1024-42.
3. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis. Eur Heart J 2006;27:178-86.
4. Bittrier V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993;270:1702-7.
5. Doust JA, Pietrzak E, Dobson A, Glasziou P How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. Br Med J 2005;330:1-9.
6. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
7. Januzzi JL, van Kimmenade R, Lainchbury J, et al. Nt-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients. Eur Heart J 2006;27:330-7.
8. Clerico A, Fontana M, Zyw L, Passion, C, Erndin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: A systematic review. Clin Chem 2007;53:813-22.
9. Del Ry S, Passino C, Emdin M, Gipnnessi D. C-type natriuretic peptide and heart failure. Pharmacol Res 2006;54:326-33.
10. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
11. Myers J, Buchanan N, Walsh D, et al. Comparison of the ramp versus standard exercise protocols. J Am Coll Cardiol 1991;17:1334-42.
12. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM, Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
13. Jabbour A, Keogh A, Hayward C, Macdonald P. Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail 2007;9:674-7.
14. Bruschi G, Ribera E, Lanfranconi M, et al. Bridge to transplantation with the MicroMed DeBakey ventricular assist device axial pump: A single centre report. J Cardiovasc Med (Hagerstown) 2006;7:114-8.
15. Kirklin JK, Holman WL. Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol 2006;21:120-6.
16. Delgado DH, Rao V, Ross HJ. Donor management in cardiac transplantation. Can J Cardiol 2002; 18:1217-23.
17. Oz MC, Kherani AR, Rowe A, et al. How to improve organ donation: Results of the ISHLT/FACT poll. J Heart Lung Transplant 2003;22:389-410.
18. Poston RS, Griffith BP. Heart transplantation. J Intensive Care Med 2004;19:3-12.
19. Zaroff JG, et al. Consensus conference report: Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations, March 28-29, 2001, Crystal City, VA. Circulation 2002;106:836-41.
20. Hornby K, et al. Non-utilization of hearts and lungs after consent for donation: A Canadian multicentre study. Can J Anaesth 2006;53:831-7.
21. Wheeldon DR, et al. Transforming the "unacceptable" donor: Outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995;14:734-42.
22. Stoica SC, et al. Noradrenaline use in the human donor and relationship with load-independent right ventricular contractility. Transplantation 2004;78:1193-7.
23. Stoica SC, Satchithananda DK, White PA, et al. Brain death leads to abnormal contractile properties of the human donor right ventricle. J Thorac Cardiovasc Surg 2006;132:116-23.
24. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987;43:852-4.
25. Canadian Cardiac Transplant Network. Adult Listing Status Criteria - revised October 2006. (Version current at February 18, 2009; access to members only)
26. Canadian Cardiac Transplant Network. Paediatric Listing Status Criteria - revised October 2006. (Version current at February 18, 2009; access to members only)
27. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150-60.
28. Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996;94:294-7.
29. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 2002;21:644-50.
30. Gebel HM, Bray RA. Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 2000;69:1370-4.
31. Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. Ann Thorac Surg 2003;75:S58-65.
32. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120-5.
33. De Marco T, Damon LE, Colombe B, Keith F, Chatterjee K, Garovoy MR. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997;16:360-5.
34. Turk JL, Poulter LW. Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine-125 I and 51 Cr. Int Arch Allergy Appl Immunol 1972;43:620-9.
35. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients waiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77:542-8.
36. Balfour IC, Fiore A, Graff RJ, Knuntsen AP. Use of rixtuximab to decrease panel reactive antibodies. J Heart Lung Transplant 2005;24:628-30.
37. Salzberg SP, Lachat ML, von Harbau K, Zund G, Turina MI. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 2005;27:222-5.
38. Hertz MI, Aurora P, Christie JD, et al. Registry of the International Society for Heart and Lung Transplantation: A quarter century of thoracic transplantation. J Heart Lung Transplant 2008;27:937-42.
39. Rajek A, Pernerstorfer T, Kastrier J, et al. Inhaled nitric oxide reduces pulmonary vascular resistance more than prostaglandin E (1) during heart transplantation. Anesth Analg 2000;90:523-30.
40. Theodoraki K, Tsiapras D, Tsourelis L, et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 2006;50:1213-7.
41. Arafa OE, Geiran OR, Andersen K, Fosse E, Simonsen S, Svennevig JL. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg 2000;70:1587-93.
42. Taghavi S, Zuckermann A, Ankersmit J, et al. Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation. Ann Thorac Surg 2004;78:1644-9.
43. Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005;24:392-400.
44. Uber PA, Mehra MR. Induction therapy in heart transplantation: Is there a role? J Heart Lung Transplant 2007;26:205-9.
45. Kirk AD. Induction immunosuppression. Transplantation 2006;82:593-602.
46. Segovia J, Rodriguez-Lambert JL, Crespo-Liero MG, et al. A randomized multicenter trial of basiliximab and muromonab (OKT3) in heart transplanation: SIMCOR study. Transplantation 2006;81:1542-8.
47. Flaman F, Zieroth S, Rao V, et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart tranplantation. J Heart Lung Transplant 2006;25:1358-62.
48. Carrier M, Leblanc M-H, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis after heart transplantation: A non-inferiority trial. J Heart Lung Transplant 2007;26:258-63.
49. Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007;26:693-9.
50. Mehra M, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Transplant 2005;24:1297-304.
51. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:2705-13.
52. Cantarovich M, Ross H, Arizon JM, et al. A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction. Am J Transplant 2005; 11:249. (Abst)
53. Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: Improvement in clinical outcomes. J Heart Lung Transplant 2005;24:1343-6.
54. Kobashigawa JA, Miller LW, Russell SD. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86.
55. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: A large European trial. Am J Transplant 2006;6:1387-97.
56. Opelz G, Dohler B, Laux G, for the Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005;5:720-8.
57. Rosenbaum DH, Adams BC, Mitchell JD, et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 2006;82:637-44.
58. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66:507-15.
59. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005;24:517-25.
60. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial. Am J Transplant 2006;6:993-7.
61. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58.
62. Eisen H. Long-term cardiovascular risk in transplantation.: Insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006;21:iii9-iii13.
63. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary heart disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694-700.
64. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58-69.
65. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710-20.
66. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody mediated rejection of cardiac transplants. J Heart Lung Transplant 2006;25:153-9.
67. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. Am J Transplant 2004;4:1523-8.
68. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998;27:1266-77.
69. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170:22-48.
70. Health Canada. Canadian Immunization Guide, 6th edn. Ottawa: Health Canada, 2002.
71. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001;1:185-91.
72. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5:218-27.
73. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001;3:97-103.
74. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-8.
75. Poston RS, Husain S, Sorce D, et al. LVAD bloodstream infections: Therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant 2003;22:9141-21.
76. Argenziano M, Catanese KA, Moazami N, et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997;16:822-31.
77. Morgan JA, Park Y, Oz MC, Naka Y. Device related infections while on left ventricular assist device support do not adversely impact bridging to transplant or posttransplant survival. Asaio J 2003;49:748-50.
78. Sinha P, Chen JM, Flannery M, Scully BE, Oz MC, Edwards NM. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 2000;102:III194-9.
79. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001;33:S38-46.
80. Milpied N, Vasseur B, Parquet N, et al. Humanized anti CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11:113-6.
81. Haddad M, Pflugfelder PW, Guiraudon C, et al. Angiographic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts. J Heart Lung Transplant 2008;24:1218-25.
82. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:1736-40.
83. Kogin J, Muscholl M, Petrakopoulou P, et al. Tacrolimus excels cyclosporine A in prevention of cardiac allograft vasculopathy - prospective IVUS, angiography and Doppler study. J Heart Lung Transplant 2002;21:68. (Abst 37)
84. Bilchick K, Henrikson C, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004;148:200-10.
85. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694, 700.
86. Mancini D, Pinney S, Burkhoff, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53.
87. Rihal C, Lerman A, Kushawaha SS. Conversion of sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-33.
88. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58.
89. Hiatt WR, Nissen S. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: Report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville MD. Circulation 2006;113:e394-5.
90. Lamich R, Ballester M, Marti V, et al. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol 1998;32:413-9.
91. Mancini D, Pinney S, Burkoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53.
92. Raichlin E, Bae J, Khalpey Z, et al. Conversion of sirolimus as primary inummosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-33.
93. Benza RL, Brown RN, Kirklin JK, et al. Palliation of allograft vasculopathy with transluminal angioplasty - a decade of experience. J Heart Lung Transplant 2002;21:74-5. (Abst 55)
94. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society of Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report - 2007. J Heart Lung Transplant 2007;26:769-81.
95. Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1424-33.
96. Haddad H. Cardiac retransplantation: An ethical dilemma. Curr Opin Cardiol 2006;21:118-9.